RGEN News and Press, Repligen Corporation From 08/02/22

Repligen press release ( NASDAQ: RGEN ): Q2 Non-GAAP EPS of $0.91 beats by $0.20 . Revenue of $207.63M (+27.4% Y/Y) beats by $18.57M . FY2022 outlook : Total revenue is expected to be in the range of $790M-$810M, an increase from previous guidance of $770M-...

Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year) Strong organic revenue growth of 29% and strong base business growth of 41% for the quarter Revenue guidance raised to $790 - $8...

Repligen ( NASDAQ: RGEN ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. EPS Estimate is $0.71 (-10.1% Y/Y) and the consensus Revenue Estimate is $189.06M (+16.0% Y/Y). has beaten EPS estimates 100% of the time and has beaten reven...

Repligen presents with many of the risk premia investors are paying a premium for in FY22. However, it has also bifurcated to the downside from peers and the benchmark, suggesting recent returns may be sector beta. We note valuations and relative ROIC are potential concerns in the...

Gainers: 1Life Healthcare ONEM +67% . Tabula Rasa HealthCare ( TRHC ) +27% . Cano Health ( CANO ) +15% . Repligen ( RGEN ) +15% . Oak Street Health ( OSH ) +10% . Losers: LumiraDx LMDX -25% . Verve Therapeuti...

UBS started off coverage on Repligen ( NASDAQ: RGEN ) with a Buy rating and $213 price target as part of a broader research note on life sciences & diagnostic tools. The analyst is positive on the company being most levered to biologics and large pharma trends, stating tha...

WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2022 financial results on Tuesday, August 2, 2022. The Company will issue a press release before the market opens and will host a conference c...

LRT Capital is a fundamental investment hedge fund. We invest only in companies with durable competitive advantages, i.e. “moats.”. May’s results for the LRT Economic Moat Strategy were below expectations. The effectiveness of our hedging strategy has been lim...

WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly 30 years of...

There's no way to sugarcoat it -- 2022 has been a rough time for the market. It seems that the decline has hit all sectors and all kinds of stocks. One sector that has been hit particularly hard is healthcare , down more than 11% year to date. As painful as that can be for sharehol...